Cargando…

Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients

Background: Neuroblastoma is the most common solid extracranial tumor in children. Patients affected by neuroblastoma are stratified into low, intermediate, and high risk in terms of event-free and overall survival. Some high-risk patients have an additional risk of acute hemorrhagic complications d...

Descripción completa

Detalles Bibliográficos
Autores principales: Voglino, Valerio, Persano, Giorgio, Crocoli, Alessandro, Castellano, Aurora, Serra, Annalisa, Giordano, Ugo, Natali, Gian Luigi, Di Paolo, Pier Luigi, Martucci, Cristina, Stracuzzi, Alessandra, Inserra, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635199/
https://www.ncbi.nlm.nih.gov/pubmed/34869118
http://dx.doi.org/10.3389/fped.2021.761896
_version_ 1784608254863605760
author Voglino, Valerio
Persano, Giorgio
Crocoli, Alessandro
Castellano, Aurora
Serra, Annalisa
Giordano, Ugo
Natali, Gian Luigi
Di Paolo, Pier Luigi
Martucci, Cristina
Stracuzzi, Alessandra
Inserra, Alessandro
author_facet Voglino, Valerio
Persano, Giorgio
Crocoli, Alessandro
Castellano, Aurora
Serra, Annalisa
Giordano, Ugo
Natali, Gian Luigi
Di Paolo, Pier Luigi
Martucci, Cristina
Stracuzzi, Alessandra
Inserra, Alessandro
author_sort Voglino, Valerio
collection PubMed
description Background: Neuroblastoma is the most common solid extracranial tumor in children. Patients affected by neuroblastoma are stratified into low, intermediate, and high risk in terms of event-free and overall survival. Some high-risk patients have an additional risk of acute hemorrhagic complications during induction chemotherapy. Aim: To find easily and rapidly assessed parameters that help clinicians identify those patients affected by high-risk neuroblastoma who have an additional risk of hemorrhagic complications. Methods: The clinical notes of patients diagnosed with high-risk neuroblastoma from January 2013 until February 2021 were retrospectively reviewed. Clinical, demographic and laboratory data, biological characteristics of the tumor, and information about treatment and hospital stay were identified. Results: In the examined period, 44 patients were diagnosed with high-risk neuroblastoma. Four of these patients had hemorrhagic complications within 2–7 days after the initiation of induction chemotherapy; two patients had hemothorax, one patient had hemoperitoneum and one patient had hemothorax and hemoperitoneum. The patient with isolated hemoperitoneum was treated with blood components transfusions, clotting factors and colloids infusions; the three patients with hemothorax underwent thoracostomy tube placement and respiratory support. At initial presentation, patients who suffered from hemorrhagic complications had a higher degree of hypertension (stage 2, p = 0.0003), higher levels of LDH (median 3,745 U/L, p = 0.009) and lower levels of hemoglobin (mean 7.6 gr/dl, p = 0.0007) compared to other high-risk patients. Conclusions: A subgroup of “additional” high-risk patients can be identified within the high-risk neuroblastoma patients based on mean arterial pressure, LDH levels and hemoglobin levels at presentation. Further studies to define cut-off values and optimal management strategies for these patients are needed.
format Online
Article
Text
id pubmed-8635199
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86351992021-12-02 Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients Voglino, Valerio Persano, Giorgio Crocoli, Alessandro Castellano, Aurora Serra, Annalisa Giordano, Ugo Natali, Gian Luigi Di Paolo, Pier Luigi Martucci, Cristina Stracuzzi, Alessandra Inserra, Alessandro Front Pediatr Pediatrics Background: Neuroblastoma is the most common solid extracranial tumor in children. Patients affected by neuroblastoma are stratified into low, intermediate, and high risk in terms of event-free and overall survival. Some high-risk patients have an additional risk of acute hemorrhagic complications during induction chemotherapy. Aim: To find easily and rapidly assessed parameters that help clinicians identify those patients affected by high-risk neuroblastoma who have an additional risk of hemorrhagic complications. Methods: The clinical notes of patients diagnosed with high-risk neuroblastoma from January 2013 until February 2021 were retrospectively reviewed. Clinical, demographic and laboratory data, biological characteristics of the tumor, and information about treatment and hospital stay were identified. Results: In the examined period, 44 patients were diagnosed with high-risk neuroblastoma. Four of these patients had hemorrhagic complications within 2–7 days after the initiation of induction chemotherapy; two patients had hemothorax, one patient had hemoperitoneum and one patient had hemothorax and hemoperitoneum. The patient with isolated hemoperitoneum was treated with blood components transfusions, clotting factors and colloids infusions; the three patients with hemothorax underwent thoracostomy tube placement and respiratory support. At initial presentation, patients who suffered from hemorrhagic complications had a higher degree of hypertension (stage 2, p = 0.0003), higher levels of LDH (median 3,745 U/L, p = 0.009) and lower levels of hemoglobin (mean 7.6 gr/dl, p = 0.0007) compared to other high-risk patients. Conclusions: A subgroup of “additional” high-risk patients can be identified within the high-risk neuroblastoma patients based on mean arterial pressure, LDH levels and hemoglobin levels at presentation. Further studies to define cut-off values and optimal management strategies for these patients are needed. Frontiers Media S.A. 2021-11-16 /pmc/articles/PMC8635199/ /pubmed/34869118 http://dx.doi.org/10.3389/fped.2021.761896 Text en Copyright © 2021 Voglino, Persano, Crocoli, Castellano, Serra, Giordano, Natali, Di Paolo, Martucci, Stracuzzi and Inserra. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Voglino, Valerio
Persano, Giorgio
Crocoli, Alessandro
Castellano, Aurora
Serra, Annalisa
Giordano, Ugo
Natali, Gian Luigi
Di Paolo, Pier Luigi
Martucci, Cristina
Stracuzzi, Alessandra
Inserra, Alessandro
Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
title Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
title_full Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
title_fullStr Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
title_full_unstemmed Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
title_short Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
title_sort hemorrhage during induction chemotherapy in neuroblastoma: additional risk factors in high-risk patients
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635199/
https://www.ncbi.nlm.nih.gov/pubmed/34869118
http://dx.doi.org/10.3389/fped.2021.761896
work_keys_str_mv AT voglinovalerio hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT persanogiorgio hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT crocolialessandro hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT castellanoaurora hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT serraannalisa hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT giordanougo hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT nataligianluigi hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT dipaolopierluigi hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT martuccicristina hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT stracuzzialessandra hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT inserraalessandro hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients